Evaluating the clinical and cost-effectiveness of permissive hypotension in critically ill patients aged 65 years or over with vasodilatory hypotension

Intensive Care National Audit & Research Centre0 个研究点目标入组 2,600 人开始时间: 2017年4月11日最近更新: 2024年5月13日

适应症

试验速览

2019 Protocol article in https://doi.org/10.1177/1751143719870088 (added 13/09/2019) 2020 Results article in https://www.ncbi.nlm.nih.gov/pubmed/32049269 (added 13/02/2020) 2021 Results article in https://pubmed.ncbi.nlm.nih.gov/33648623/ (added 03/03/2021) 2020 Protocol article in https://pubmed.ncbi.nlm.nih.gov/34093727/ (added 03/05/2024)

•Current inclusion criteria as of 16/02/2018:
•1. Age 65 years or older
•2. Vasodilatory hypotension as assessed by treating clinician
•3. Started infusion (for at least one hour) of vasopressors within prior 6 hours (if noradrenaline, then a minimum dose of 0.1 µg kg-1 min-1)
•4. Adequate fluid resuscitation is completed or ongoing
•5. Vasopressors expected to continue for 6 hours or more as assessed by treating clinician
•Previous inclusion criteria:
•1. Age 65 years or older
•2. Vasodilatory hypotension as assessed by treating clinician
•3. Decision to start vasopressors or started within prior 6 hours following/during adequate fluid resuscitation
•4. Vasopressors expected to continue for 6 hours or more as assessed by treating clinician

•1. Vasopressors being used solely as therapy for bleeding, acute ventricular failure (left or right) or post-cardiopulmonary bypass vasoplegia
•2. Ongoing treatment for brain injury or spinal cord injury
•3. Death perceived as imminent
•4. Previous enrolment to the 65 Trial

发起方

Intensive Care National Audit & Research Centre